We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Adding Topotecan to Standard Treatment for Ovarian Cancer Does Not Improve Progression-Free Survival.
- Abstract
The article discusses a research study on the addition of topotecan to the standard treatment of ovarian cancer. It references a study published in the October 11, 2010 issue of "The Journal of the National Cancer Institute." The study included 819 women, aged 28 to 78 from Canada and Europe, who were newly-diagnosed with stage IIB or more advanced ovarian cancer. Study authors concluded that carboplatin plus paclitaxel is the best standard of care for epithelial ovarian cancer stage IIB or greater.
- Subjects
CANADA; EUROPE; OVARIAN tumors; TOPOTECAN; PACLITAXEL; CANCER patients
- Publication
JNCI: Journal of the National Cancer Institute, 2010, Vol 102, Issue 20, pNP
- ISSN
0027-8874
- Publication type
Article
- DOI
10.1093/jnci/djq437